Home/Pipeline/Cytoprime2 Community Care Study

Cytoprime2 Community Care Study

Effectiveness of EndoSign® in community care settings for early esophageal cancer detection

Clinical TrialActive

Key Facts

Indication
Effectiveness of EndoSign® in community care settings for early esophageal cancer detection
Phase
Clinical Trial
Status
Active
Company

About Cyted Health

Cyted Health is a commercial-stage diagnostics company focused on revolutionizing the early detection of gastrointestinal diseases, particularly esophageal cancer and its precursor, Barrett's Esophagus. Its core technology is the EndoSign® capsule sponge, a minimally invasive device for cell collection, which is integrated with advanced molecular diagnostics. The company has achieved significant milestones including FDA 510(k) clearance, initiation of a major UK screening trial (BEST4), and a $44 million Series B financing round to accelerate US expansion.

View full company profile